The global cephalosporin drugs market was valued at USD 11.6 billion in 2018 and is expected to grow at a CAGR of 5.2% during the forecast period. Cephalosporin may be a bactericidal, broad-spectrum, β-lactam antibiotic originally derived from the fungus Acremonium that's wont to treat bacterial infections like pneumonia, skin infections, streptococcal sore throat, staph infections, tonsillitis, bronchitis, otitis, gonorrhea, et al. It resembles penicillin and hence is employed as an alternative for patients who are allergic to penicillin. a rise in the incidence of the population affected by pneumonia, tonsillitis, bronchitis, and gonorrhea drives the market growth.
Key Developments in Cephalosporin Drugs Market:
• In April 2019, Autolus Therapeutics PLC was granted with an orphan drug designation, to autolus enriched T-cells, genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 for the treatment of Respiratory Tract Infection (ALL), by the US FDA
• In April 2019, Cellectis received approval from the US FDA to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM).
• In May 2018, Kite Pharma leased a new facility for cell therapy engineering in Europe in the Netherlands with the aim of strengthening its position on the global market for CAR T-cell therapy.

The key leading players in the market include Ranbaxy, Merck, Sandoz, Pfizer, Astellas, Roche, Bristol-Myers Squibb, Abbott, Lupin Pharmaceuticals, Teva Pharmaceuticals, and Glaxo SmithKline.